Human induced pluripotent stem cells to unravel the pathophysiology of peripartum cardiomyopathy

Completed

• Conditions: 10019280; Peripartum cardiomyopathy; pregnancy-related heart failure

• Registration Number: NL-OMON40927
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 July 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

Patients:
• Ages from 18 and older.
• Diagnosis PPCM according to the revised European Society of Cardiology guidelines 2012.
• Participation of healthy sister (or female cousin) that has been pregnant at least once without diagnosis of PPCM.
• Possibility of adequate communication.
• Informed consent is obtained.;Controls:
• Ages from 18 and older.
• Sister or (female) first cousin of patient.
• Generally in good health.
• Has been pregnant without cardiac complications.
• Possibility of adequate communication.
• Informed consent is obtained.

Exclusion Criteria

Patients:
• Other etiology of heart failure other than PPCM.
• A healthy sister (or female cousin) cannot be included, for any reason.
• Severe complications during pregnancy (aside from PPCM).
• Extensive skin disorder precluding a biopsy from unaffected skin area.
• Known allergy for local anesthetics.
• Informed consent can, for whatever reason, not be obtained.;Controls:
• Has never been pregnant.
• Severe complications during pregnancy (including cardiac complications)
• Extensive skin disorder precluding a biopsy from unaffected skin area.
• Known allergy for local anesthetics.
• Informed consent can, for whatever reason, not be obtained.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- IPS cells can be generated from skin fibroblasts of test subjects and can be<br /><br>differentiated into cardiomyocytes.<br /><br>- Cardiomyocytes derived from test subjects via IPS reprogramming show<br /><br>differences in expression profiles and in responses to stress in comparison to<br /><br>those of healthy controls.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable</p><br>